Filing Details

Accession Number:
0000950170-24-062585
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-05-20 18:30:26
Reporting Period:
2024-05-20
Accepted Time:
2024-05-20 18:30:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1422143 Kura Oncology Inc. KURA Pharmaceutical Preparations (2834) 611547851
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1813058 Brophy Teresa Bair C/O Kura Oncology, Inc.
12730 High Bluff Drive, Suite 400
San Diego CA 92130
Chief Legal Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-05-20 2,615 $22.15 68,979 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2023.
  2. 2615 shares were acquired on May 17, 2024 pursuant to the Issuer's Employee Stock Purchase Plan.
  3. This transaction was executed in multiple trades at prices ranging from $22.06 to $22.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. The reported sale of 2,615 shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 22, 2023.